Early access
Sign in
Taking people in ItalyPhase 1

Long-term follow-up of people treated with genetically modified cell therapies

Monitors people from earlier cell therapy studies for late side effects of their treatment.

Key facts

Who runs it
USWM Ct LLC
Where
Milan, ItalySee the siteAlso in 3 other countries, 3 sites
Registry title
Long-Term Follow-Up (LTFU) of Participants Treated with Adoptive Cell Therapies
Status
Recruiting
Phase
Phase 1
People taking part
7 people, planned
Started
14 Sept 2020
Expected to end
4 May 2038
Type of study
Interventional
Record updated
14 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people who have already received at least one dose of an ADP cell therapy and finished or left an earlier ADP study or access program. They are followed over time for late side effects.

Sex
Women and men can join.
Earlier treatment
Must have received at least one dose of an ADP adoptive cell therapy. Must have completed or withdrawn from an ADP-sponsored or supported study, or completed treatment through managed access to an adoptive cell therapy.

Main reasons for not taking part

  • The record lists no exclusion criteria.

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Participants who have received at least one dose of ADP adoptive cell therapy agent
  • Participants who have completed ADP sponsored or supported interventional study or have withdrawn from it
  • Participants who have completed treatment as part of managed access to an adoptive cell therapy
  • Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
  • The investigator is responsible for review of medical history
  • Capable of giving signed informed consent

Who cannot take part

  • None

Where in Italy

Also in 3 other countries, 3 sites

  • Fondazione IRCCS - Istituto Nazionale dei TumoriMilan, ItalyTaking people

About the trial

What the trial wants to find out

To monitor participants for delayed AEs associated with administration of autologous cells that have been genetically modified.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
Long-Term Follow-Up (LTFU) of Participants Treated with Adoptive Cell Therapies
Plain-language title
Long-term follow-up of people treated with genetically modified cell therapiesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
14 August 2026